- Home
- RGC vs OSTX Comparison
RGC vs OSTX Comparison
Compare RGC & OSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- OSTX
- Stock Information
- Founded
- RGC 2014
- OSTX 2018
- Country
- RGC Hong Kong
- OSTX United States
- Employees
- RGC N/A
- OSTX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- OSTX
- Sector
- RGC Health Care
- OSTX
- Exchange
- RGC Nasdaq
- OSTX NYSE
- Market Cap
- RGC 105.3M
- OSTX 109.6M
- IPO Year
- RGC 2021
- OSTX 2024
- Fundamental
- Price
- RGC $4.82
- OSTX $2.95
- Analyst Decision
- RGC
- OSTX Strong Buy
- Analyst Count
- RGC 0
- OSTX 2
- Target Price
- RGC N/A
- OSTX $17.50
- AVG Volume (30 Days)
- RGC 6.7K
- OSTX 1.1M
- Earning Date
- RGC 10-25-2024
- OSTX 02-15-2025
- Dividend Yield
- RGC N/A
- OSTX N/A
- EPS Growth
- RGC N/A
- OSTX N/A
- EPS
- RGC N/A
- OSTX N/A
- Revenue
- RGC N/A
- OSTX N/A
- Revenue This Year
- RGC N/A
- OSTX N/A
- Revenue Next Year
- RGC N/A
- OSTX $26,663.99
- P/E Ratio
- RGC N/A
- OSTX N/A
- Revenue Growth
- RGC N/A
- OSTX N/A
- 52 Week Low
- RGC $3.03
- OSTX $1.58
- 52 Week High
- RGC $32.44
- OSTX $7.00
- Technical
- Relative Strength Index (RSI)
- RGC 44.37
- OSTX N/A
- Support Level
- RGC $4.81
- OSTX N/A
- Resistance Level
- RGC $4.95
- OSTX N/A
- Average True Range (ATR)
- RGC 0.24
- OSTX 0.00
- MACD
- RGC 0.03
- OSTX 0.00
- Stochastic Oscillator
- RGC 19.92
- OSTX 0.00
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.